Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
A new configuration of the I-SPY Platform, named I-SPY2.2, introduces sequential multiple-assignment randomization to improve matching of therapy …
Phase III SEQUOIA-HCM analyses show aficamten offers benefit to patients with varying symptom severity and across regions, opening …
New oral vaccine succeeds against multiple cholera strains offering promise for broad use in endemic regions
A new antibody-drug conjugate brings hope for patients with lung cancer who have few options
Combination therapy delivers promising efficacy and manageable safety in PD-1 refractory head and neck squamous cell carcinoma
Already a subscriber? Log in